Clinical trials: Recurrent Vulvovaginal Candidiasis
Vulvovaginal Candidiasis, Genital, Laser Therapy
A Protocol for the Role of Fractional CO2 Laser in Consolidation Treatment of Recurrent Vulvovaginal Candidiasis
Background: Recurrent vulvovaginal candidiasis (RVVC) is a common obstinate vulvovaginal inflammation in gynecology. At present, the pathogenesis of RVVC is not clear.
- Trial name
- NCT04292704
- Testing
- the fractional CO2 laser, Clotrimazole
- Where
- China
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital of Wenzhou Medical University
Recurrent Vulvovaginal Candidiasis
A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis
The purpose of this study is to evaluate the Efficacy and Safety of SHR8008 capsule In Subjects With Recurrent Vulvovaginal Candidiasis
- Trial name
- NCT05074602
- Testing
- SHR8008, Fluconazole
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Vulvovaginal Candidiasis
Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC)
A prospective study to evaluate the efficacy of classic homeopathic therapy compared to maintenance itraconazole therapy with and without additional exogenous lactobacillus for treatment of recurrent Candida vaginitis.
- Trial name
- NCT00895453
- Testing
- itraconazole, lactobacillus gasseri, classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)
- Where
- Austria
- Volunteers
- 144 people
- Sponsor
- Medical University of Vienna
Invasive Candidiasis, Mucocutaneous Candidiasis
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or…
- Conditions
- Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis
- Trial name
- FURI (NCT03059992)
- Testing
- Ibrexafungerp
- Where
- 37 sites in United States, Austria and 6 more
- Volunteers
- 233 people
- Sponsor
- Scynexis, Inc.
Recurrent Vulvovaginal Candidiasis
A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast infections, is defined as at least 3 episodes of acute VVC in the past 12 months.
- Trial name
- VIOLET (NCT03562156)
- Testing
- Oteseconazole (VT-1161)
- Where
- 25 sites in United States
- Volunteers
- 438 people
- Sponsor
- Mycovia Pharmaceuticals Inc.
Recurrent Vulvovaginal Candidiasis
A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
VT-1161 is a novel, oral inhibitor of fungal lanosterol demethylase (CYP51). In vitro and in vivo pharmacology studies have demonstrated that VT-1161 is highly active against Candida albicans and also non-albicans Candida species…
- Trial name
- NCT02267382
- Testing
- VT-1161
- Where
- 32 sites in United States
- Volunteers
- 254 people
- Sponsor
- Viamet
Recurrent Vulvovaginal Candidiasis
Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study
In this study, the pentavalent bioconjugate candidate vaccine (Candi5V) against Candida will be tested to obtain first-time-in-human (FTIH) data on its safety, immunogenicity, and preliminary efficacy in women with recurrent…
- Trial name
- NCT06190509
- Testing
- Vaccine
- Where
- 7 sites in Belgium, Poland
- Volunteers
- 251 people
- Sponsor
- LimmaTech Biologics AG
Recurrent Vulvovaginal Candidiasis
Effect of a Lactobacillus Strain on the Prevention of Recurrent Vaginal Candidiasis
The objective of this study is to evaluate the efficacy of the consumption of the one probiotic strain in the prevention of new vaginal candidiasis events in women with recurrent vaginal candidiasis.
- Trial name
- NCT04639544
- Testing
- Lactobacillus strain
- Where
- Spain
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Biosearch S.A.
Recurrent Vulvovaginal Candidiasis
Blue Light Emitting Diode Therapy on Vulvovaginal Candidiasis
With the knowledge that VVC is an infectious disease of the genitourinary tract that is common in women of reproductive age, and because of the shortage of non-drug therapies for this condition, this study will aim to evaluate…
- Trial name
- NCT05795491
- Testing
- Blue Light Emitting Diode Therapy, Azole Antifungal
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
Vulvovaginal Candidiasis
Oral Lactobacillus Crispatus Lc-G22 as Adjunctive Therapy for Vulvovaginal Candidiasis
This single-center, randomized, single-blind, placebo-controlled trial aimed to evaluate the efficacy and safety of oral Lactobacillus crispatus Lc-G22 as adjunctive therapy to clotrimazole for preventing recurrence of…
- Trial name
- NCT07727967
- Testing
- Lactobacillus crispatus Lc-G22
- Where
- China
- Volunteers
- 100 people
- Sponsor
- BioGrowing Co., Ltd
Recurrent Vulvovaginal Candidiasis
A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC)
This is a prospective, randomized, multi-center, active-controlled, double-blind, double-dummy, multicenter, non-inferiority study comparing the clinical efficacy, safety and tolerability of ProF-001 to fluconazole.
- Trial name
- NCT04734405
- Testing
- Prof-001, Fluconazole 150 mg
- Where
- 29 sites in Austria, Poland and 1 more
- Volunteers
- 432 people
- Sponsor
- ProFem GmbH
Candidiasis, Vulvovaginal, Yeast Infection
Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization
Non-interventional extension study to investigate VVC recurrence and candida colonization following the P2 acute VVC study
- Conditions
- Candidiasis, Vulvovaginal, Yeast Infection, Mycoses, Moniliasis, Vulvovaginal
- Trial name
- NCT02888197
- Where
- 23 sites in United States
- Volunteers
- 32 people
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Candidiasis, Vulvovaginal, Recurrent Candidiasis of Vagina
Fluconazol Versus Medical Honey in the Treatment of Recurrent Vulvovaginal Candidiasis
The purpose of this study is to compare the efficacy of Flucanzol versus L-mesitran in the treatment of patients with recurrent vulvovaginal candidiasis. The investigator will look at vaginal swabs after 1, 6 and 12 months.
- Trial name
- NCT04626258
- Testing
- Fluconazole, L-Mesitran
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Recurrent Vulvovaginal Candidiasis
Study of Lactobacillus in Adjuvant Treatment of RVVC
We are trying to determine if Clotrimazole vaginal tablets with oral Lactobacillus is better than Clotrimazole vaginal tablets in Preventing the Recurrence of vulvovaginalcandidiasis
- Trial name
- NCT04699240
- Testing
- clotrimazole vaginal tablets, Clotrimazole vaginal tablets+ Lactobacillus
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Peking University Shenzhen Hospital
Vulvovaginal Candidiasis
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
This is a multi-center, randomized, double-blind, placebo-controlled study intended to assess the safety, tolerability and humoral and cellular immune response over a 12-month period after receiving one dose of either the NDV-3A…
- Trial name
- NCT01926028
- Testing
- NDV-3A, NDV-3
- Where
- 20 sites in United States
- Volunteers
- 188 people
- Sponsor
- NovaDigm Therapeutics, Inc.
Recurrent Vulvovaginal Candidiasis
Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections
Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast infections, is defined as at least 3 episodes of acute vulvovaginal candidiasis (VVC) in the past 12 months.
- Trial name
- ultraVIOLET (NCT03840616)
- Testing
- Oteseconazole (VT-1161) 150mg capsule, Fluconazole 150mg capsule
- Where
- 33 sites in United States
- Volunteers
- 219 people
- Sponsor
- Mycovia Pharmaceuticals Inc.
Vulvovaginal Candidiasis, Vaginal Yeast Infections
Zinc-containing Vaginal Gel and Oral Fluconazole for Vulvovaginal Candidiasis.
Vaginitis is one of the most common gynecological problems in women. Candida albicans is responsible for more than 85% of vaginal fungal infections and reinfection after standard treatment is quite common.
- Trial name
- NCT05895162
- Testing
- JUVIA zinc containing vaginal gel treatment, Fluconazole 150Mg Tab
- Where
- Hungary
- Volunteers
- 64 people
- Sponsor
- FEMPHARMA Kft.
Recurrent Vulvovaginal Candidiasis
A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast infections, is defined as at least 3 episodes of acute VVC in the past 12 months.
- Trial name
- VIOLET (NCT03561701)
- Testing
- Oteseconazole (VT-1161)
- Where
- 14 sites in United States
- Volunteers
- 425 people
- Sponsor
- Mycovia Pharmaceuticals Inc.
Recurrent Vulvovaginal Candidiasis
Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)
This study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral ibrexafungerp (formerly "SCY-078") compared to placebo in female subjects 12 years and older…
- Trial name
- CANDLE (NCT04029116)
- Testing
- Fluconazole Tablet, IBREXAFUNGERP
- Where
- 25 sites in United States
- Volunteers
- 440 people
- Sponsor
- Scynexis, Inc.
Vulvovaginal Candidiasis
Effect of a Multi-strain Probiotic on Recurrent Vulvovaginal Candidiasis
This study evaluates the effect of a multi-strain probiotic on the risk of recurrence and severity of symptoms in females with recurrent vulvovaginal candidiasis (R-VVC).
- Trial name
- PROVELIA (NCT06480604)
- Testing
- Probiotic
- Where
- 6 sites in India
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- The Archer-Daniels-Midland Company